# Jazz Pharmaceuticals clinical trials: 206 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 206 trials with Jazz Pharmaceuticals as lead sponsor, 18 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Jazz Pharmaceuticals: 206 rows for $10.30, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/jazz-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 206
- Recruiting or not yet: 18
- Read on: November 19, 2026

## Trials

The 25 newest of 206, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 10, 2026 | NCT07813663 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in Healthy Male and Female Participants | Jazz Pharmaceuticals | Phase 1 | Recruiting | Healthy Participants | 212 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07813663) |
| August 24, 2026 | NCT07780968 | Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA | Jazz Pharmaceuticals | Observational | Not yet recruiting | Esophageal Cancer, GastroEsophageal Cancer, Gastroesophageal-junction Cancer, HER2-positive Gastric Cancer, Stomach... | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780968) |
| July 27, 2026 | NCT07728097 | A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS | Jazz Pharmaceuticals | Phase 4 | Not yet recruiting | Lennox-Gastaut Syndrome | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07728097) |
| July 23, 2026 | NCT07723976 | A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE | Jazz Pharmaceuticals | Phase 3 | Recruiting | Developmental and Epileptic Encephalopathy (DEE) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723976) |
| July 23, 2026 | NCT07723963 | A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy | Jazz Pharmaceuticals | Phase 2/3 | Recruiting | Juvenile Myoclonic Epilepsy | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723963) |
| June 4, 2026 | NCT07625280 | A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH | Jazz Pharmaceuticals | Phase 3 | Recruiting | Narcolepsy, Idiopathic Hypersomnia | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07625280) |
| April 16, 2026 | NCT07533942 | A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma | Jazz Pharmaceuticals | Phase 2 | Recruiting | Meningioma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07533942) |
| March 10, 2026 | NCT07459634 | A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC | Jazz Pharmaceuticals | Phase 2 | Recruiting | Extensive-stage Small-cell Lung Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07459634) |
| January 30, 2026 | NCT07377539 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants | Jazz Pharmaceuticals | Phase 1 | Active not recruiting | Healthy Participants | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07377539) |
| December 15, 2025 | NCT07282587 | Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma | Jazz Pharmaceuticals | Phase 2 | Recruiting | Advanced Pheochromocytoma and Paraganglioma, PCPG | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07282587) |
| November 18, 2025 | NCT07233239 | A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS \[GWP42003-P, JZP926\]) for the Treatment of Focal-Onset... | Jazz Pharmaceuticals | Phase 1 | Recruiting | Focal Seizures | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07233239) |
| August 3, 2025 | NCT07102381 | A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | Jazz Pharmaceuticals | Phase 2 | Recruiting | HER2-positive Breast Cancer, Breast Cancer | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07102381) |
| May 7, 2025 | NCT06961266 | A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy... | Jazz Pharmaceuticals | Phase 1 | Terminated | Narcolepsy | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06961266) |
| November 19, 2024 | NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Jazz Pharmaceuticals | Phase 2 | Recruiting | Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06695845) |
| May 30, 2024 | NCT06435429 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the... | Jazz Pharmaceuticals | Phase 3 | Recruiting | Metastatic HER2-positive Breast Cancer | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06435429) |
| February 28, 2024 | NCT06282575 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract... | Jazz Pharmaceuticals | Phase 3 | Recruiting | Biliary Tract Cancer | 286 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06282575) |
| November 22, 2023 | NCT06143839 | VYxeoS Liposomal Italian Observational Study iN the Real Practice | Jazz Pharmaceuticals | Observational | Completed | Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Therapy-Related Acute Myeloid... | 113 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06143839) |
| November 2, 2023 | NCT06113237 | Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy | Jazz Pharmaceuticals | Observational | Recruiting | Maternal Complications, Pregnancy Complication, Birth Outcomes, Adverse, Pregnancy | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06113237) |
| October 30, 2023 | NCT06108050 | JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | Jazz Pharmaceuticals | Phase 1 | Recruiting | Advanced Solid Tumor, Metastatic Solid Tumor | 177 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06108050) |
| May 25, 2023 | NCT05875974 | A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic... | Jazz Pharmaceuticals | Phase 4 | Completed | Idiopathic Hypersomnia, Narcolepsy | 199 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05875974) |
| May 22, 2023 | NCT05869773 | A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy | Jazz Pharmaceuticals | Phase 4 | Completed | Narcolepsy | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05869773) |
| May 18, 2023 | NCT05864846 | A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of... | Jazz Pharmaceuticals | Phase 4 | Completed | Tuberous Sclerosis Complex Associated Neuropsychiatric Disease | 79 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05864846) |
| March 16, 2023 | NCT05772429 | Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting | Jazz Pharmaceuticals | Observational | Completed | Seizures | 158 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05772429) |
| February 17, 2023 | NCT05734066 | Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | Jazz Pharmaceuticals | Phase 1/2 | Recruiting | Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05734066) |
| February 17, 2023 | NCT05733390 | A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder | Jazz Pharmaceuticals | Phase 2 | Withdrawn | Irritability Associated With Autism Spectrum Disorder, Autism Spectrum Disorder, ASD | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05733390) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 29 |
| Phase 1/2 | 8 |
| Phase 2 | 59 |
| Phase 2/3 | 4 |
| Phase 3 | 70 |
| Phase 4 | 10 |
| Not applicable | 8 |
| Observational | 17 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 133 |
| Terminated | 28 |
| Recruiting | 16 |
| Withdrawn | 11 |
| Active not recruiting | 6 |
| No longer available | 4 |
| Approved for marketing | 4 |
| Unknown | 2 |
| Not yet recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Pain | 18 |
| Narcolepsy | 17 |
| Epilepsy | 16 |
| Multiple Sclerosis | 16 |
| Leukemia, Myeloid, Acute | 14 |
| Seizures | 11 |
| Muscle Spasticity | 10 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 |
| Lennox Gastaut Syndrome | 7 |
| Epilepsies, Myoclonic | 7 |
| Glioma | 7 |
| Neoplasms | 7 |
| Tuberous Sclerosis | 6 |
| Adenoviridae Infections | 6 |
| Marijuana Abuse | 6 |
| Stomach Neoplasms | 5 |
| Disorders of Excessive Somnolence | 5 |
| Fibromyalgia | 5 |
| Sleep Apnea, Obstructive | 5 |
| Neoplasm Metastasis | 4 |
| Hepatic Veno-Occlusive Disease | 4 |
| Leukemia | 4 |
| Colorectal Neoplasms | 4 |
| Esophageal Neoplasms | 4 |
| Peripheral Nervous System Diseases | 4 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Irish pubs in the United States](https://specstream.ai/data/businesses/irish-pubs/united-states)
- [Health food restaurants in the United States](https://specstream.ai/data/businesses/health-food-restaurants/united-states)
- [Filipino restaurants in the United States](https://specstream.ai/data/businesses/filipino-restaurants/united-states)
- [Duplication companies in the United States](https://specstream.ai/data/businesses/duplication-companies/united-states)
- [Community health centers in the United States](https://specstream.ai/data/businesses/community-health-centers/united-states)
